Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Hillel Yaffe Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00834145
First received: February 2, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted

February 2, 2009
February 2, 2009
March 2009
December 2009   (final data collection date for primary outcome measure)
Patient weight [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Leg circumference, Pulmonary pressures, Cardiac function [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure
Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure: Short- Intermediate- and Long-Term Outcomes

Mobilization of fluid from the legs with the Normatec pump in patients with right heart failure, may empty the "reservoir" in the legs from excessive fluid, enabling fluid overload to collect there rather than in the liver or in other third spaces. Thus, we hypothesize that patients will lose weight, feel better, look better, be less prone to infections in their legs and to congestion of the liver.

The protocol will be divided into 2 parts:

  1. The initial pumping phase will be an in-hospital study, short term study. Patients will be randomly assigned to conventional/conservative treatment or to pump therapy. Within 24 hours of admission patients assigned to pump therapy will be recruited for the study and will begin therapy according to the protocol outlined in the table below. These patients will not be given diuretics unless required to because of shortness of breath with suspected left heart failure. Individualized programs regarding pumping frequency and pump parameters will be set for each patient and will be adjusted during the first few days and maintained throughout the study unless there is a reason to modify them.

    Data on both the conventional/conservative and the pump arms of the study will be collected at similar intervals. The duration of the in-hospital period will not be extended because of the study and is expected to be 3-7 days.

  2. An intermediate-term study in which the patients from the phase 1 study will be ambulatory. During this phase of the study the effect of continuous maintenance and optimization will be monitored. Patients will come to the hospital for their pumping session at which time the protocol tests will be performed. Patients that were assigned to the conventional/conservative arm in phase 1 will be examined as per protocol at 1, 2 and 3 weeks after admission but BNP levels will be repeated only after the 3rd week.
  3. At 3 and 6 months after admission, the "long term" phase of the study, a systematic investigation regarding repeat hospitalizations and their causes will be carried out by telephone interview and by a review of admission data from hospital records.
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Right Heart Failure
  • Cor Pulmonale
Device: A mechanical compression pump
Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
Other Name: NormaTec Pump
  • Experimental: 1
    Patients will receive a NormaTec pump and perform active pumping twice daily during hospitalization and thereafter once daily in addition to routine medical therapy.
    Intervention: Device: A mechanical compression pump
  • No Intervention: 2
    Routine medical treatment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
30
December 2009
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hospitalized patients
  • Adults
  • Right heart failure secondary to pulmonary hypertension (cor pulmonale)
  • Pronounced leg edema

Exclusion Criteria:

  • Patients in sepsis
  • Hemodynamically unstable
  • Renal failure (creatinine >2 mg%)
  • Deep vein thrombosis
  • Pregnancy
  • Psychiatric/noncompliant patients
  • Patients who will not sign the informed consent form
Both
30 Years and older
No
Contact: David S. Blondheim, MD 972-46304488 blond@netvision.net.il
Israel
 
NCT00834145
32/2008
Not Provided
David Blondheim, M.D., Hillel Yaffe Medical Center
Hillel Yaffe Medical Center
Not Provided
Not Provided
Hillel Yaffe Medical Center
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP